""Is it right to assume an AG will cause decline in pricing of enoxaparin,"" Orangeone...the generic price should remain where it is. Looks like SNY will absorb a drop in gross profits to protect its market share (and MNTA's). ...SNY IS OBVIOUSLY INITIATING THIS MOVE TO MAKE ANY THIRD OR FOURTH GENERIC LAUNCH UNPALATABLE AS POSSIBLE... y3